目的探讨窄带成像(narrow band imaging,NBI)宫腔镜在子宫内膜癌及内膜非典型增生诊断中的应用价值。方法 2009年6月～2011年6月,对189例异常子宫出血可疑子宫内膜病变患者行电子宫腔镜检查,对宫腔内膜依次使用白光和NBI模式进行分类和...目的探讨窄带成像(narrow band imaging,NBI)宫腔镜在子宫内膜癌及内膜非典型增生诊断中的应用价值。方法 2009年6月～2011年6月,对189例异常子宫出血可疑子宫内膜病变患者行电子宫腔镜检查,对宫腔内膜依次使用白光和NBI模式进行分类和病灶性质的判断,以病理诊断作为金标准,比较两种观察模式对子宫内膜癌及内膜非典型增生诊断的作用。结果 189例共取子宫内膜病理标本334份,其中病理阳性病灶(包括子宫内膜癌及子宫内膜非典型增生)127份,阴性病灶(正常子宫内膜及内膜良性病变)207份。依照子宫内膜癌及子宫内膜非典型增生的宫腔镜下诊断特征:病灶增厚高出周边内膜、异型血管和(或)组织坏死致病灶表面毛糙不规则,NBI及白光宫腔镜对子宫内膜癌及内膜非典型增生诊断的准确率为93.7%(313/334)及84.7%(283/334)(χ2=14.010,P=0.000),敏感性为95.3%(121/127)及79.5%(101/127)(χ2=14.302,P=0.000),NBI模式均显著高于白光;二者诊断的特异性为92.8%(192/207)及87.9%(182/207)(χ2=2.767,P=0.096),差异无显著性。结论 NBI弥补了普通光宫腔镜对病变形态学识别的不足,可明显提高对子宫内膜癌及内膜非典型增生诊断的敏感性和准确率,NBI指导下的对宫腔内病变的定位活检具有良好的临床应用前景。展开更多
Objective To evaluate the efficacy of medroxyprogesterone acetate(MA)plus metformin as the primary fertility-sparing treatment for atypical endometrial hyperplasia(AEH)and early-stage grade 1 endometrial adenocarcinom...Objective To evaluate the efficacy of medroxyprogesterone acetate(MA)plus metformin as the primary fertility-sparing treatment for atypical endometrial hyperplasia(AEH)and early-stage grade 1 endometrial adenocarcinoma(G1 EAC)and the recurrence rate after treatment.Methods Sixty patients(aged 20-42 years)with AEH and/or grade 1 EAC limited to the endometrium were enrolled prospectively and randomized into two groups(n=30)to receive oral MA treatment at the daily dose of 160 mg(control)or MA plus oral metformin(850 mg,twice a day)for at least 6 months.The treatment could extend to 12 months until a complete response(CR)was achieved,and follow-up hysteroscopy and curettage were performed every 3 months.For all the patients who achieved CR,endometrial expressions of IGFBP-rP1,p-Akt and p-AMPK were detected immunohistochemically.Results A total of 58 patients completed the treatment.After 9 months of treatment,23(76.7%)patients in the combined treatment group and 20(71.4%)in the control group achieved CR;two patients in the control group achieved CR after converting to the combined treatment.The recurrence rate did not differ significantly between the control group and combined treatment group(30.0%vs 22.7%,P>0.05).Ten(35.7%)patients in the control group experienced significant weight gain of 5.7±6.1 kg,while none of the patients receiving the combined treatment exhibited significant body weight changes.Compared with the control group,the patients receiving the combined treatment showed enhanced endometrial expressions of IGFBP-rP1 and p-AMPK with lowered p-Akt expression.Conclusion Metformin combined with MA may provide an effective option for fertility-sparing treatment of AEH and grade 1 stage IA EAC,and the clinical benefits of metformin for controlling MA-induced weight gain and promoting endometrial expressions of IGFBP-rP1 and p-AMPK while inhibiting p-Akt expression warrants further study.展开更多
文摘Objective To evaluate the efficacy of medroxyprogesterone acetate(MA)plus metformin as the primary fertility-sparing treatment for atypical endometrial hyperplasia(AEH)and early-stage grade 1 endometrial adenocarcinoma(G1 EAC)and the recurrence rate after treatment.Methods Sixty patients(aged 20-42 years)with AEH and/or grade 1 EAC limited to the endometrium were enrolled prospectively and randomized into two groups(n=30)to receive oral MA treatment at the daily dose of 160 mg(control)or MA plus oral metformin(850 mg,twice a day)for at least 6 months.The treatment could extend to 12 months until a complete response(CR)was achieved,and follow-up hysteroscopy and curettage were performed every 3 months.For all the patients who achieved CR,endometrial expressions of IGFBP-rP1,p-Akt and p-AMPK were detected immunohistochemically.Results A total of 58 patients completed the treatment.After 9 months of treatment,23(76.7%)patients in the combined treatment group and 20(71.4%)in the control group achieved CR;two patients in the control group achieved CR after converting to the combined treatment.The recurrence rate did not differ significantly between the control group and combined treatment group(30.0%vs 22.7%,P>0.05).Ten(35.7%)patients in the control group experienced significant weight gain of 5.7±6.1 kg,while none of the patients receiving the combined treatment exhibited significant body weight changes.Compared with the control group,the patients receiving the combined treatment showed enhanced endometrial expressions of IGFBP-rP1 and p-AMPK with lowered p-Akt expression.Conclusion Metformin combined with MA may provide an effective option for fertility-sparing treatment of AEH and grade 1 stage IA EAC,and the clinical benefits of metformin for controlling MA-induced weight gain and promoting endometrial expressions of IGFBP-rP1 and p-AMPK while inhibiting p-Akt expression warrants further study.
